Clinical trial
STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of…
NCT00050635 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00050635 |
|---|---|
| Title | STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Collaborators | Quintiles, Inc. Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Neoplasms, Diarrhea |
| Intervention type | Drug |
| Interventions | Sandostatin LAR Depot |
| Enrollment | 150 |
| Start date | Dec 1, 2002 |
| Completion | Jul 1, 2003 |
| First posted | Dec 18, 2002 |
| Last update posted | Nov 19, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: